Trade-Ideas: Salix Pharmaceuticals (SLXP) Is Today's Post-Market Leader Stock

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Trade-Ideas LLC identified Salix Pharmaceuticals ( SLXP) as a post-market leader candidate. In addition to specific proprietary factors, Trade-Ideas identified Salix Pharmaceuticals as such a stock due to the following factors:

  • SLXP has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $320.2 million.
  • SLXP is up 15.7% today from today's close.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in SLXP with the Ticky from Trade-Ideas. See the FREE profile for SLXP NOW at Trade-Ideas

More details on SLXP:

Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs and medical devices to treat various gastrointestinal diseases in the United States. SLXP has a PE ratio of 185.8. Currently there are 9 analysts that rate Salix Pharmaceuticals a buy, no analysts rate it a sell, and 3 rate it a hold.

The average volume for Salix Pharmaceuticals has been 1.4 million shares per day over the past 30 days. Salix has a market cap of $10.2 billion and is part of the health care sector and drugs industry. The stock has a beta of 0.90 and a short float of 17.3% with 4.86 days to cover. Shares are up 82.6% year-to-date as of the close of trading on Friday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

After Clearing Valeant Litigation, Jaguar and Napo Pharmaceuticals Reunite

Biotech Hits an Inflection Point

Put Agenus, Progenics on Your Small-Cap List

Put Agenus, Progenics on Your Small-Cap List

Put Agenus, Progenics on Your Small-Cap List

Put Agenus, Progenics on Your Small-Cap List

2 Small Biopharma Stocks on the Move

2 Small Biopharma Stocks on the Move